CoChat

Esketamine for treatment resistant depression: a trick of smoke and mirrors?

Open access
Gastaldon, C., Papola, D., Ostuzzi, G., Barbui, C. · 2020 · Epidemiology and Psychiatric Sciences

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index; none of the 31 sources its claims cite is checked for support yet.

Abstract

In March 2019, the US Food and Drug Administration (FDA) approved a nasal spray formulation of esketamine for the treatment of resistant depression in adults. Esketamine is the S-enantiomer of ketamine, an FDA-approved anaesthetic, known to cause dissociation and, occasionally, hallucinations. While ketamine has not been approved for depression in the USA or in any other country, it has been used off-label in cases of severe depression. This commentary critically reviewed the evidence on esketamine submitted to the FDA, aiming to draw implications for clinical practice, research and regulatory science.

Overview

CoChat Summary

TL;DR

This commentary argues that the FDA evidence package for esketamine in treatment-resistant depression (TRD) shows only modest short-term benefit, with substantial concerns about acceptability and dissociation. The authors conclude that the approval relied on limited placebo-controlled evidence and that larger pragmatic trials are urgently needed.

Key findings

  • The FDA evidence base comprised four phase III trials; three were short-term placebo-controlled efficacy trials in TRD, and one was a withdrawal trial (SUSTAIN-1) with 297 patients randomized to continue esketamine + AD (N = 152) or switch to placebo nasal spray while continuing AD (N = 145).
  • In the short-term trials, only TRANSFORM-2 showed a significant benefit: MADRS change at day 28 was −21.4 with esketamine + AD vs −17.0 with placebo + AD, a mean difference of 4.4 points.
  • Re-analysis of the three short-term studies found an overall mean difference of −4.08 on MADRS (95% CI −6.20 to 1.97; I² = 0%; 3 studies; 641 participants), which the authors note is below the 6.5-point difference they cite as clinically significant from the trial authors.
  • Acceptability was worse with esketamine: dropout due to any cause was higher than placebo (RR = 1.63; 95% CI 1.02–2.60; I² = 0%; 3 studies; 711 participants), and dissociation risk was reported as almost seven times higher than placebo, with about 25% of esketamine-treated patients experiencing severe dissociation.

Methods

  • Narrative commentary based on a review of FDA-submitted esketamine documentation; the authors searched the FDA website using the term “esketamine” up to June 2019 and independently inspected downloaded documents.
  • The paper re-analyzed phase III trial data using standard Cochrane meta-analytical methods to extract and pool efficacy and acceptability outcomes.
  • The main analyses reported were pooled estimates for MADRS change, dropout due to any cause, and dissociation.

Limitations

  • The paper states that the evidence base is limited by the explanatory nature of the existing studies and that long-term data are completely lacking.
  • The authors note that the withdrawal design in SUSTAIN-1 tends to overemphasize maintenance efficacy because the comparison group stops treatment abruptly after improvement.
  • Evident from the text: the review is based on FDA-submitted trials only and does not include direct comparisons with an active comparator; the authors explicitly say that evidence against placebo, rather than against an active comparator, was used for approval.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1017/s2045796019000751

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1. Mean difference between esketamine and placebo at day 28 (study endpoint) measured with the Montgomery–Asberg Depression Rating Scale (MADRS).
Fig. 1. Mean difference between esketamine and placebo at day 28 (study endpoint) measured with the Montgomery–Asberg Depression Rating Scale (MADRS).CC BY · PubMed Central
Fig. 2. Acceptability of esketamine v. placebo at day 28 (study endpoint), measured as drop-outs due to any cause.
Fig. 2. Acceptability of esketamine v. placebo at day 28 (study endpoint), measured as drop-outs due to any cause.CC BY · PubMed Central
Fig. 3. Risk of dissociation of esketamine v. placebo, measured as the proportion of patients experiencing this adverse effect.
Fig. 3. Risk of dissociation of esketamine v. placebo, measured as the proportion of patients experiencing this adverse effect.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 5 Not valid · 21 Not checked · 28 Own results and interpretations

42 more claims

Create a free account to see all 54 claims and to verify the 31 references still open.

See all claims — free account
  • Probably not a substantial claim. 6
  • It may state two separate claims as one. 3

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 20 references

Research works printed but not linked: 1

  1. 2018, Depression in Adults: Recognition and Management Clinical Guideline (CG90)

Cited by

See all 54

Metadata

Authors
Gastaldon, C., Papola, D., Ostuzzi, G., & Barbui, C.
Affiliations
University of Verona (IT)
Corresponding author
Gastaldon, C.
Venue
Epidemiology and Psychiatric Sciences
Published
2019-12-16
Volume
29
Pages
e79-e79
ISSN
  • 2045-7960 (ISSN-L)
  • 2045-7979
OpenAlex
W2995768649
Cited by
54
References
20
Citations by year
2026: 4 · 2025: 8 · 2024: 14 · 2023: 3 · 2022: 8 · 2021: 7 · 2020: 10
FWCI
3.87
Type
journal article
Language
en
Open access
Locations
  • Epidemiology and Psychiatric Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • INFM-OAR (INFN Catania) (submittedVersion, cc-by)
  • Zenodo (CERN European Organization for Nuclear Research) (cc-by)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Keywords
esketamine, treatment-resistant depression, ketamine, nasal spray formulation, FDA approval, off-label drug use, dissociation, hallucinations, regulatory science, evidence base
MeSH terms
Adult, Antidepressive Agents, Depression, Humans, Infusions, Intravenous, Ketamine, United States, United States Food and Drug Administration, Drug Approval, Evidence-Based Medicine, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Esketamine for treatment resistant depression: a trick of smoke and mirrors? https://app.cochat.ai/papers/10.1017/s2045796019000751
The paper
Gastaldon, C., Papola, D., Ostuzzi, G., & Barbui, C. (2020). Esketamine for treatment resistant depression: a trick of smoke and mirrors? Epidemiology and Psychiatric Sciences. https://doi.org/10.1017/s2045796019000751

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.